Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of health-care services provider Accretive Health (NYSE: AH) were up as much as 19% in intraday trading today as investors reacted to analyst upgrades.

So what: After taking a drubbing yesterday, Accretive Health's stock bounced back in a big way today as Wall Street analysts put their thumbs up on the stock. Briefing.com lists Robert W. Baird as providing an upgrade and it appears to also erroneously list Brean Murray downgrading it (my sources show that Brean Murray actually upgraded the stock). I was able to get my hands on research from some other Wall Street shops and there was similarly bullish commentary there as well, with a few suggesting to buy on the post-sell-off weakness.

Now what: I think Wall Street has a tendency to get a bit too excited about growth sometimes; with average long-term growth estimates of 40% on Accretive, it wouldn't surprise me if that was the case here. Additionally, the company pretty recently had its IPO and -- though this issue was ostensibly cleared up after the dot-com bubble burst -- it wouldn't surprise me if the firms behind the IPO had a little extra interest in seeing the stock succeed. In fact, Baird was on the underwriting team, as was JPMorgan Chase (NYSE: JPM) and Morgan Stanley (NYSE: MS), both of which had some positive thoughts out on the stock today. Of course, on the plus side, if you're excited about Accretive Health, you know that, at least for now, Wall Street's got your back!

Want to keep up to date on Accretive Health? Add it to your watchlist here by clicking here.

The Fool owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.                                                                                       

Fool contributor Matt Koppenheffer does not own shares of any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy assures you no Wookiees were harmed in the making of this article.